About This Conference:
Healthtech Institute’s eleventh annual conference on RNAi for Functional
Genomics Screening will cover the latest in the use of RNA interference (RNAi)
screens for identifying and validating new drug targets and exploring unknown
cellular pathways. It will cover everything from assay design to data analysis
for the use of in vitro and in vivo siRNA (small interfering RNA) and shRNA
(short hairpin RNA) screens, in a way that will evoke thought-provoking
discussions and inspire collaborations.
FEATURED PRESENTATION: Functional RNAi Screens for Cancer in Mice
Elaine Fuchs, Ph.D., Rebecca C.
Lancefield Professor and Investigator, Howard Hughes Medical Institute,
Laboratory of Mammalian Cell Biology and Development, The Rockefeller University
In vivo Target Validation with Viral Vectors: Translating In vitro
Hits to In vivo Functions
Ki Jeong Lee, Ph.D., Principal Scientist,
Genome Analysis Unit, Amgen, Inc.
Superstar to Washed-Up Delinquent: Is it Time to Abandon RNAi Screening?
Martin, Ph.D., Team Leader, RNAi Screening, NIH Chemical Genomics Center, NIH
Center for Translational Therapeutics, National
Institutes for Health
Cell-Based Screening to Empower
Human Genetics: Moving from Gene to Genetic Variants
M.D., Director of Human Genetics, Merck Research Laboratories
A High Content Screen of an
Arrayed cDNA Library for Modulators of Adipogenic Differentiation
Patrick Collins, Ph.D., Senior Scientist,
Genome Analysis Unit, Amgen Inc.
Functional Dissection of Coding
and Long Non-coding Transcripts in Pluripotent Cells
Buchholz, Ph.D., Professor, Medical Systems Biology, UCC, University Hospital and Medical
Faculty Carl Gustav Carus, Technische Uuniversitat Dresden
First Screens Using a LncRNA
siRNA Library: Shedding Some Light on
the Dark Matter of the Transcriptome
Buehler, Ph.D., Group Leader, Informatics, National Center for Advancing
Translational Sciences National Institutes of Health
Using ncRNAs to Identify Cancer Cell Vulnerabilities
Alexander Pertsemlidis, Ph.D.,
Associate Professor, Greehey Children's Cancer Research Institute, University
of Texas Health Science Center at San Antonio
RNAi is Dead, Long Live RNAi: Reinventing the RNAi Screening
Samuel Hasson, Ph.D.,
Principal Investigator, Neuroscience, Pfizer, Inc.
RNAi Screens for Identification
of Rare Genetic Disease Treatments
Gibson, CEO, Administration & R&D, Recursion Pharmaceuticals
Phenotypic Screening: Opportunities and Challenges
Jing Li, Ph.D., Director of Genomics and
Phenotypic Screening, Merck Research Laboratories